NUVB Stock Overview
A clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Nuvation Bio Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.59 |
| 52 Week High | US$4.16 |
| 52 Week Low | US$1.43 |
| Beta | 1.46 |
| 1 Month Change | -10.38% |
| 3 Month Change | 7.47% |
| 1 Year Change | 72.67% |
| 3 Year Change | -61.52% |
| 5 Year Change | n/a |
| Change since IPO | -73.30% |
Recent News & Updates
Is Nuvation Bio (NYSE:NUVB) Using Debt In A Risky Way?
Nov 20
Nuvation Bio: Competitive Data In ROS1+ NSCLC, Strong Cash, Smallish Market
Oct 21Recent updates
Is Nuvation Bio (NYSE:NUVB) Using Debt In A Risky Way?
Nov 20Nuvation Bio: Competitive Data In ROS1+ NSCLC, Strong Cash, Smallish Market
Oct 21Nuvation Bio: Continuing To Justify A Buy Thesis With Catalysts In 2024
Aug 08Is Nuvation Bio (NYSE:NUVB) A Risky Investment?
Aug 07Nuvation Bio: A Potentially Transformative Acquisition
Jun 20Nuvation Bio: Strong Buy Off The Acquisition Of A Late-Stage Lung Cancer Candidate
Mar 31Nuvation: Cash Is King, Science Is An Afterthought
Oct 03We Think Nuvation Bio (NYSE:NUVB) Can Afford To Drive Business Growth
Sep 14Seth Klarman's Baupost adds Herbalife, Altice USA, exits Dropbox, Enhabit
Feb 14We're Hopeful That Nuvation Bio (NYSE:NUVB) Will Use Its Cash Wisely
Feb 10We Think Nuvation Bio (NYSE:NUVB) Can Afford To Drive Business Growth
Nov 09Nuvation Bio GAAP EPS of -$0.12 beats by $0.02
Nov 03Shareholder Returns
| NUVB | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -8.2% | -1.7% | -2.6% |
| 1Y | 72.7% | 3.2% | 24.5% |
Return vs Industry: NUVB exceeded the US Pharmaceuticals industry which returned 3.2% over the past year.
Return vs Market: NUVB exceeded the US Market which returned 24.5% over the past year.
Price Volatility
| NUVB volatility | |
|---|---|
| NUVB Average Weekly Movement | 10.1% |
| Pharmaceuticals Industry Average Movement | 10.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: NUVB has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: NUVB's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 203 | David Hung | www.nuvationbio.com |
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company’s lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.
Nuvation Bio Inc. Fundamentals Summary
| NUVB fundamental statistics | |
|---|---|
| Market cap | US$895.27m |
| Earnings (TTM) | -US$532.28m |
| Revenue (TTM) | US$2.16m |
403.2x
P/S Ratio-1.6x
P/E RatioIs NUVB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NUVB income statement (TTM) | |
|---|---|
| Revenue | US$2.16m |
| Cost of Revenue | US$2.86m |
| Gross Profit | -US$700.00k |
| Other Expenses | US$531.58m |
| Earnings | -US$532.28m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.58 |
| Gross Margin | -32.38% |
| Net Profit Margin | -24,619.84% |
| Debt/Equity Ratio | 1.7% |
How did NUVB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 00:39 |
| End of Day Share Price | 2025/01/02 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Nuvation Bio Inc. is covered by 7 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Clarence Powell | BMO Capital Markets Equity Research |
| Robert Burns | H.C. Wainwright & Co. |
| Michael Yee | Jefferies LLC |